Advertisement
Journal of Investigative Dermatology Home

Targeted Therapies in Autoimmune Skin Diseases

Published:October 29, 2021DOI:https://doi.org/10.1016/j.jid.2021.08.439
      Unlike the established anti-inflammatory drugs with a broad range, new-targeted therapeutic approaches have emerged in the management of autoimmune skin diseases to increase efficacy and decrease adverse reactions on the basis of an improved molecular understanding of pathogenesis. Most inflammatory dermatoses are driven by misled immune responses physiologically directed at exogenous pathogens, that is, type 1 immunity against viral pathogens, type 2 immunity against parasites, and type 3 immunity against fungi and bacteria. Pathogenic hallmarks of these major immune reaction patterns are characterized within this article, and a comprehensive overview of current clinical trials evaluating targeted therapeutics for respective dermatoses is outlined.

      Abbreviations:

      AD (atopic dermatitis), BP (bullous pemphigoid), CLE (cutaneous lupus erythematosus), DC (dendritic cell), DM (dermatomyositis), FDA (Food and Drug Administration), ID (interface dermatitis), ILC (innate lymphoid cell), KC (keratinocyte), LP (lichen planus), LS (lichen sclerosus), MTX (methotrexate), pDC (plasmacytoid dendritic cell), PDE4 (phosphodiesterase 4), PRR (pattern-recognition receptor), PV (pemphigus vulgaris), STAT (signal transducer and activator of transcription), Th (T helper type), TLR (toll-like receptor)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aikawa N.
        • Kawasaki Y.
        Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome.
        Ther Clin Risk Manag. 2014; 10: 621-629
        • Aki A.
        • Tanaka K.
        • Nagaoka N.
        • Kimura T.
        • Baba D.
        • Onodera Y.
        • et al.
        Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation.
        FASEB Bioadv. 2020; 2: 478-488
        • Annunziato F.
        • Romagnani C.
        • Romagnani S.
        The 3 major types of innate and adaptive cell-mediated effector immunity.
        J Allergy Clin Immunol. 2015; 135: 626-635
        • Antonczyk A.
        • Krist B.
        • Sajek M.
        • Michalska A.
        • Piaszyk-Borychowska A.
        • Plens-Galaska M.
        • et al.
        Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease.
        Front Immunol. 2019; 10: 1176
        • Barrat F.J.
        • Crow M.K.
        • Ivashkiv L.B.
        Interferon target-gene expression and epigenomic signatures in health and disease.
        Nat Immunol. 2019; 20: 1574-1583
        • Belge K.
        • Brück J.
        • Ghoreschi K.
        Advances in treating psoriasis.
        F1000Prime Rep. 2014; 6: 4
        • Bhat P.
        • Leggatt G.
        • Waterhouse N.
        • Frazer I.H.
        Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity.
        Cell Death Dis. 2017; 8e2836
        • Braegelmann C.
        • Fetter T.
        • Niebel D.
        • Dietz L.
        • Bieber T.
        • Wenzel J.
        Immunostimulatory endogenous nucleic acids perpetuate interface dermatitis-translation of pathogenic fundamentals into an in vitro model.
        Front Immunol. 2020; 11: 622511
        • Braegelmann J.
        • Braegelmann C.
        • Bieber T.
        • Wenzel J.
        Candida induces the expression of IL-36γ in human keratinocytes: implications for a pathogen-driven exacerbation of psoriasis?.
        J Eur Acad Dermatol Venereol. 2018; 32: e403-e406
        • Bryan A.M.
        • Del Poeta M.
        Sphingosine-1-phosphate receptors and innate immunity.
        Cell Microbiol. 2018; 20e12836
        • Buhl A.L.
        • Wenzel J.
        Interleukin-36 in infectious and inflammatory skin diseases.
        Front Immunol. 2019; 10: 1162
        • Calautti E.
        • Avalle L.
        • Poli V.
        Psoriasis: a STAT3-centric view.
        Int J Mol Sci. 2018; 19: 171
        • Capone A.
        • Volpe E.
        Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases.
        Front Immunol. 2020; 11: 348
        • Dai C.
        • Me R.
        • Gao N.
        • Su G.
        • Wu X.
        • Yu F.X.
        Role of IL-36γ/IL-36R signaling in corneal innate defense against Candida albicans keratitis.
        Invest Ophthalmol Vis Sci. 2021; 62: 10
        • Eberle F.C.
        • Brück J.
        • Holstein J.
        • Hirahara K.
        • Ghoreschi K.
        Recent advances in understanding psoriasis.
        F1000Res. 2016; 5: 770
        • Edwards G.
        • Diercks G.F.H.
        • Seelen M.A.J.
        • Horvath B.
        • van Doorn M.B.A.
        • Damman J.
        Complement activation in autoimmune bullous dermatoses: a comprehensive review.
        Front Immunol. 2019; 10: 1477
        • Eyerich K.
        • Eyerich S.
        Immune response patterns in non-communicable inflammatory skin diseases.
        J Eur Acad Dermatol Venereol. 2018; 32: 692-703
        • Fetter T.
        • Niebel D.
        • Braegelmann C.
        • Wenzel J.
        Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches.
        Cells. 2020; 9: 2627
        • Fetter T.
        • Rios G.C.
        • Niebel D.
        • Bieber T.
        • Wenzel J.
        Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the Janus kinase inhibitor Ruxolitinib.
        Acta Derm Venereol. 2020; 100adv00144
        • Fiorentino D.F.
        The Yin and Yang of TNF-{alpha} inhibition.
        Arch Dermatol. 2007; 143: 233-236
        • Fishman P.
        • Cohen S.
        The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
        Clin Rheumatol. 2016; 35: 2359-2362
        • Freire P.C.
        • Muñoz C.H.
        • Stingl G.
        IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.
        Br J Dermatol. 2017; 177: 1644-1653
        • Frentsch M.
        • Stark R.
        • Matzmohr N.
        • Meier S.
        • Durlanik S.
        • Schulz A.R.
        • et al.
        CD40L expression permits CD8+ T cells to execute immunologic helper functions.
        Blood. 2013; 122: 405-412
        • Furie R.
        • Khamashta M.
        • Merrill J.T.
        • Werth V.P.
        • Kalunian K.
        • Brohawn P.
        • et al.
        Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.
        Arthritis Rheumatol. 2017; 69: 376-386
        • Furie R.
        • Werth V.P.
        • Merola J.F.
        • Stevenson L.
        • Reynolds T.L.
        • Naik H.
        • et al.
        Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
        J Clin Invest. 2019; 129: 1359-1371
        • Galli S.J.
        The mast cell-IgE paradox: from homeostasis to anaphylaxis.
        Am J Pathol. 2016; 186: 212-224
        • Ghirardello A.
        • Bassi N.
        • Palma L.
        • Borella E.
        • Domeneghetti M.
        • Punzi L.
        • et al.
        Autoantibodies in polymyositis and dermatomyositis.
        Curr Rheumatol Rep. 2013; 15: 335
        • Gholijani N.
        • Yazdani M.R.
        • Dastgheib L.
        Predominant role of innate pro-inflammatory cytokines in vitiligo disease.
        Arch Dermatol Res. 2020; 312: 123-131
        • Granstein R.D.
        • Wagner J.A.
        • Stohl L.L.
        • Ding W.
        Calcitonin gene-related peptide: key regulator of cutaneous immunity.
        Acta Physiol (Oxf). 2015; 213: 586-594
        • Gremese E.
        • Alivernini S.
        • Tolusso B.
        • Zeidler M.P.
        • Ferraccioli G.
        JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.
        J Leukoc Biol. 2019; 106: 1063-1068
        • Handfield C.
        • Kwock J.
        • MacLeod A.S.
        Innate antiviral immunity in the skin.
        Trends Immunol. 2018; 39: 328-340
        • Hartmann S.
        • Biliouris K.
        • Naik H.
        • Rabah D.
        • Stevenson L.
        • Shen C.
        • et al.
        A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
        J Pharmacokinet Pharmacodyn. 2020; 47: 255-266
        • Ivashkiv L.B.
        IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.
        Nat Rev Immunol. 2018; 18: 545-558
        • Jain R.
        • Chen Y.
        • Kanno Y.
        • Joyce-Shaikh B.
        • Vahedi G.
        • Hirahara K.
        • et al.
        Interleukin-23-induced transcription factor Blimp-1 promotes pathogenicity of T helper 17 cells.
        Immunity. 2016; 44: 131-142
        • Kaech S.M.
        • Cui W.
        Transcriptional control of effector and memory CD8+ T cell differentiation.
        Nat Rev Immunol. 2012; 12: 749-761
        • Kakeda M.
        • Arock M.
        • Schlapbach C.
        • Yawalkar N.
        Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis.
        J Am Acad Dermatol. 2014; 70 (683–90.e1)
        • Kalia S.
        • Dutz J.P.
        New concepts in antimalarial use and mode of action in dermatology.
        Dermatol Ther. 2007; 20: 160-174
        • Khil'chenko S.
        • Boch K.
        • van Beek N.
        • Vorobyev A.
        • Zillikens D.
        • Schmidt E.
        • et al.
        Alterations of total serum immunoglobulin concentrations in pemphigus and pemphigoid: selected IgG2 deficiency in bullous pemphigoid.
        Front Med (Lausanne). 2020; 7: 472
        • Kim S.Y.
        • Hur M.S.
        • Choi B.G.
        • Kim M.J.
        • Lee Y.W.
        • Choe Y.B.
        • et al.
        A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population.
        Clin Exp Immunol. 2017; 187: 251-258
        • Klose C.S.N.
        • Artis D.
        Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity.
        Cell Res. 2020; 30: 475-491
        • Kowalewski C.
        • Hashimoto T.
        • Joly P.
        Editorial: autoimmune blistering diseases.
        Front Immunol. 2020; 11: 1614
        • Kremer N.
        • Snast I.
        • Cohen E.S.
        • Hodak E.
        • Mimouni D.
        • Lapidoth M.
        • et al.
        Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature.
        Am J Clin Dermatol. 2019; 20: 209-216
        • Kuznik A.
        • Bencina M.
        • Svajger U.
        • Jeras M.
        • Rozman B.
        • Jerala R.
        Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
        J Immunol. 2011; 186: 4794-4804
        • Lai F.Y.X.
        • Higgins E.
        • Smith C.H.
        • Barker J.N.
        • Pink A.
        Morphologic switch from psoriasiform to eczematous dermatitis after anti-IL-17 therapy: a case series.
        JAMA Dermatol. 2019; 155: 1082-1084
        • Lauffer F.
        • Jargosch M.
        • Krause L.
        • Garzorz-Stark N.
        • Franz R.
        • Roenneberg S.
        • et al.
        Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis.
        J Invest Dermatol. 2018; 138: 1785-1794
        • Leyva-Castillo J.M.
        • Galand C.
        • Mashiko S.
        • Bissonnette R.
        • McGurk A.
        • Ziegler S.F.
        • et al.
        ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation.
        J Allergy Clin Immunol. 2020; 145 (1606–14.e4)
        • Li H.
        • Zuo J.
        • Tang W.
        Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases.
        Front Pharmacol. 2018; 9: 1048
        • Lloyd C.M.
        • Snelgrove R.J.
        Type 2 immunity: expanding our view.
        Sci Immunol. 2018; 3eaat1604
        • Oyama N.
        • Chan I.
        • Neill S.M.
        • Hamada T.
        • South A.P.
        • Wessagowit V.
        • et al.
        Autoantibodies to extracellular matrix protein 1 in lichen sclerosus.
        Lancet. 2003; 362: 118-123
        • Roesner L.M.
        • Werfel T.
        Autoimmunity (or not) in atopic dermatitis.
        Front Immunol. 2019; 10: 2128
        • Rothenberg M.E.
        • Hogan S.P.
        The eosinophil.
        Annu Rev Immunol. 2006; 24: 147-174
        • Scholtissek B.
        • Zahn S.
        • Maier J.
        • Klaeschen S.
        • Braegelmann C.
        • Hoelzel M.
        • et al.
        Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus.
        J Invest Dermatol. 2017; 137: 1484-1492
        • Shao S.
        • Tsoi L.C.
        • Sarkar M.K.
        • Xing X.
        • Xue K.
        • Uppala R.
        • et al.
        IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.
        Sci Transl Med. 2019; 11: eaav7561
        • Shiohara T.
        • Mizukawa Y.
        • Takahashi R.
        • Kano Y.
        Pathomechanisms of lichen planus autoimmunity elicited by cross-reactive T cells.
        Curr Dir Autoimmun. 2008; 10: 206-226
        • Singh R.
        • Heron C.E.
        • Ghamrawi R.I.
        • Strowd L.C.
        • Feldman S.R.
        Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis.
        ImmunoTargets Ther. 2020; 9: 255-272
        • Souza-Neto J.A.
        • Sim S.
        • Dimopoulos G.
        An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense.
        Proc Natl Acad Sci USA. 2009; 106: 17841-17846
        • Stevens N.E.
        • Cowin A.J.
        • Kopecki Z.
        Skin barrier and autoimmunity-mechanisms and novel therapeutic approaches for autoimmune blistering diseases of the skin.
        Front Immunol. 2019; 10: 1089
        • Ten Bergen LL ten
        • Petrovic A.
        • Aarebrot A.K.
        • Appel S.
        Current knowledge on autoantigens and autoantibodies in psoriasis.
        Scand J Immunol. 2020; 92e12945
        • Varma A.
        • Levitt J.
        Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis.
        JAAD Case Rep. 2020; 6: 217-218
        • Verma A.H.
        • Zafar H.
        • Ponde N.O.
        • Hepworth O.W.
        • Sihra D.
        • Aggor F.E.Y.
        • et al.
        IL-36 and IL-1/IL-17 drive immunity to oral candidiasis via parallel mechanisms.
        J Immunol. 2018; 201: 627-634
        • Watanabe S.
        • Yamada Y.
        • Murakami H.
        Expression of Th1/Th2 cell-related chemokine receptors on CD4+ lymphocytes under physiological conditions.
        Int J Lab Hematol. 2020; 42: 68-76
        • Wenzel J.
        Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies.
        Nat Rev Rheumatol. 2019; 15: 519-532
        • Wenzel J.
        • Tüting T.
        An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis".
        J Invest Dermatol. 2008; 128: 2392-2402
        • Witte M.
        • Zillikens D.
        • Schmidt E.
        Diagnosis of autoimmune blistering diseases.
        Front Med (Lausanne). 2018; 5: 296
        • Yang B.
        • Suwanpradid J.
        • Sanchez-Lagunes R.
        • Choi H.W.
        • Hoang P.
        • Wang D.
        • et al.
        IL-27 facilitates skin wound healing through induction of epidermal proliferation and host defense.
        J Invest Dermatol. 2017; 137: 1166-1175